ArticleBiochemical genetics2026
Study on Immune-Related Genes and Clinical Validation of Acute Myocardial Infarction Based on Bioinformatics.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Acute myocardial infarction (AMI) is a cardiovascular disease featuring the narrowing and hardening of coronary arteries triggered by a combination of factors, which ultimately leads to the death of heart muscle. We retrieved the GSE109048 and GSE123342 datasets from the Gene Expression Omnibus (GEO) database. After integrating these datasets, we selected 154 module key genes with the help of weighted correlation network analysis (WGCNA). After that, we used protein-protein interaction networks (PPI) analysis to screen out 18 core genes in the protein interaction network from 154 genes. Finally, we used three machine learning algorithms to jointly identify three genes (CLEC4D, CLEC4E and LY96) that may predict or influence the progression of AMI. In the dataset, CLEC4D, CLEC4E and LY96 were significantly overexpressed in AMI patients. Immune infiltration analysis revealed that CLEC4D, CLEC4E and LY96 could affect the extent of immune cell infiltration. For further verification, we found that the expression levels of CLEC4D, CLEC4E and LY96 in the AMI cohort were significantly higher than those in coronary heart disease (CAD) patients by qRT-PCR. This finding corroborated the results derived from bioinformatics analysis. In summary, CLEC4D, CLEC4E and LY96 can be used to predict the occurrence of AMI.
Indexed as
Identifiers
39820825What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.